newsfilter
← Latest News
GlobeNewswire·

Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook

Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026